Vaccines and compositions against Streptococcus pneumoniae

Patent metadata

Field	Value
Publication number	US-10188717-B2
Application number	US-201615180844-A
Country	US
Kind code	B2
Filing date	Jun 13, 2016
Priority date	Jan 20, 2011
Publication date	Jan 29, 2019
Grant date	Jan 29, 2019

Abstract

Streptococcus pneumoniae is a major health concern, especially in very young, elderly, or immunocompromized patients. The present disclosure provides, inter alia, certain highly effective vaccines and pharmaceutical compositions in Streptococcus pneumoniae. The antigens may be used therapeutically or prophylactically.

First claim

We claim:

1. A method for treating a subject suffering from or susceptible to Streptococcus pneumoniae infection, comprising administering an effective amount of a vaccine formulation comprising:
(1) a first isolated polypeptide comprising an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO: 265; and
(2) a second isolated polypeptide comprising:
(a) an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO: 10, or
(b) an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO:6.

2. The method of claim 1 , wherein the method inhibits infection by S. pneumoniae in an uninfected subject.

3. The method of claim 1 , wherein the method inhibits S. pneumoniae colonization in a subject.

4. The method of claim 1 , wherein the method inhibits S. pneumoniae symptoms.

5. The method of claim 1 , wherein the method inhibits S. pneumoniae -induced sepsis.

6. The method of claim 1 , wherein the method treats a subject with one dose.

7. The method of claim 1 , wherein the method treats a subject within three doses.

8. The method of claim 1 , wherein the subject is a human.

9. The method of claim 1 , wherein:
the second isolated polypeptide comprises an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO: 10, and the vaccine formulation further comprises a third isolated polypeptide comprising an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO:6.

10. The method of claim 1 , wherein the first polypeptide comprises the amino acid sequence of SEQ ID NO:265.

11. The method of claim 1 , wherein the second polypeptide comprises the amino acid sequence of SEQ ID NO:10.

12. The method of claim 1 , wherein the second polypeptide comprises the amino acid sequence of SEQ ID NO:6.

13. The method of claim 1 , wherein at least one of the first and second polypeptides are lipidated.

14. The method of claim 9 , wherein at least one of the first, second, and third polypeptides are lipidated.

15. A method comprising:
administering a pharmaceutical composition to a subject, wherein the pharmaceutical composition includes:
(1) a first isolated polypeptide comprising an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO: 265; and
(2) a second isolated polypeptide comprising:
(a) an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO: 10, or
(b) an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO: 6.

16. The method of claim 15 , wherein the subject is a human.

17. The method of claim 15 , wherein at least one of the first and second polypeptides are lipidated.

18. The method of claim 15 , wherein the first polypeptide comprises the amino acid sequence of SEQ ID NO:265.

19. The method of claim 15 , wherein the second polypeptide comprises the amino acid sequence of SEQ ID NO:10.

20. The method of claim 15 , wherein the second isolated polypeptide comprises an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO: 10, and the pharmaceutical composition further comprises a third isolated polypeptide comprising an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO:6.

Assignees

• Genocea Biosciences Inc
• Childrens Medical Center

Inventors

• Gierahn Todd
• Malley Richard

Classifications

• A61K39/092 Primary

  Streptococcus · CPC title

• A61K39/02 Primary

  Bacterial antigens · CPC title

• A61K38/04

  Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof ({enzyme inhibitors A61K38/005;} gastrins {A61K38/2207}, somatostatins A61K38/31, melanotropins A61K38/34 {; protease inhibitors A61K38/55}) · CPC title

• A61P31/04

  Antibacterial agents · CPC title

• A61K39/39

  characterised by the immunostimulating additives, e.g. chemical adjuvants · CPC title